A phase IIIb open-label run-in and double-blind, placebo controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis.

Trial Profile

A phase IIIb open-label run-in and double-blind, placebo controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Dose-Flex-II; DoseFlex; EXTEND
  • Sponsors UCB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 01 Jun 2012 Results are to be presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top